Wall Street faces another key litmus test Thursday with results from megacaps Apple and Amazon after the bell.
Related Posts
Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%
The bank upgraded shares of the German biotechnology firm to a buy rating from neutral.
Buy this biopharmaceutical stock that can rally 25%, says RBC Capital Markets
The firm initiated coverage at an outperform rating.
How to capitalize on the market fear and generate some income using options
Jeff Kilburg describes selling a put spread on the SPDR S&P 500 ETF Trust.